Canada Markets closed

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2500+0.0700 (+2.20%)
At close: 04:00PM EST
3.3300 +0.08 (+2.46%)
After hours: 05:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.1800
Open3.2600
Bid3.2300 x 800
Ask3.2800 x 900
Day's Range3.1800 - 3.3000
52 Week Range1.7100 - 6.1000
Volume543,728
Avg. Volume1,149,150
Market Cap220.96M
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-2.7870
Earnings DateMar 08, 2023 - Mar 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.33
  • Simply Wall St.

    Investors in Gritstone bio (NASDAQ:GRTS) have unfortunately lost 66% over the last three years

    It is doubtless a positive to see that the Gritstone bio, Inc. ( NASDAQ:GRTS ) share price has gained some 32% in the...

  • GlobeNewswire

    Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 28,000 shares of its common stock with an exercise price of $3.67, which is equal to the closing price of Gritstone’s common stock on January 9, 2023, the date of the grant. These stock

  • GlobeNewswire

    Gritstone bio to Participate in Upcoming Investor Conferences

    EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences. B. Riley Securities' 3rd Annual Oncology Conference (Fireside Chat)Date and Time: Thursday, January 19, 2023 at 12:30pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer 2023 BIO CEO & Inve